Most marine-derived compounds possess a few defining characteristics. First, often very low doses are given to patients, and they are administered almost exclusively via intravenous infusion (i.v.). The compounds are typically large molecules, especially the depsipeptides, and they are often hydrophobic. These attributes make them fascinating compounds in terms of pharmacokinetics but also from a bioanalytical point of view.

The first marine-derived compound approved by the United States (US) Food and Drug Administration (FDA) was cytarabine (Cytosar U) in 1969, followed by trabectedin (Yondelis),eribulin mesylate (Halaven), brentuximab vedotin (Adcetris), and midostaurin (Rydapt) in the years 2007, 2010, 2011, 2013, and 2017, respectively.

The classification of Marine Derived Drugs includes mollusk sources, Sponge sources, tunicate sources, fish sources and others. And the proportion of mollusk sources is occupied 49.40% of global revenue market share in 2018.
North America is the largest consumption place, with a consumption market share nearly 50.55% in 2018. Following Europe, Europe is the second largest consumption place with the consumption market share of 29.87%.

According to this study, over the next five years the Marine Derived Drugs market will register a 9.1% CAGR in terms of revenue, the global market size will reach US$ 2524.4 million by 2024, from US$ 1633.3 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Marine Derived Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Marine Derived Drugs market by product type, application, key manufacturers and key regions and countries.

This study considers the Marine Derived Drugs value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Mollusk
Sponge
Tunicate
Fish
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Antitumor Drugs
Anti-Cardiovascular Drugs
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Seattle Genetics
Eisai Co
Tekada
Pfizer
Pharma Mar
Johnson and Johnson
GSK
TerSera Therapeutics
Teva

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Marine Derived Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Marine Derived Drugs market by identifying its various subsegments.
Focuses on the key global Marine Derived Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Marine Derived Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Marine Derived Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.